Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543093 | 1.00 | MAPT (0.63) | MAPTNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL3544325 | 0.93 | MAPT (0.58) | MAPTNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL11662189 | 0.87 | MAPT (0.57) | MAPTNAMPTALDH1A1SLC6A3POLB | |
| SCHEMBL3296949 | 0.85 | SMN1; SMN2 (0.55) | MAPTNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL3548042 | 0.85 | MAPT (0.46) | MAPTNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL3548044 | 0.85 | MAPT (0.46) | MAPTNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL3302195 | 0.85 | SMN1; SMN2 (0.55) | MAPTNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL3296952 | 0.85 | SMN1; SMN2 (0.55) | MAPTNAMPTALDH1A1MEN1KMT2A | |
| SCHEMBL3300911 | 0.81 | NPC1 (0.58) | MAPTNAMPTSLC18A3TDP1 | |
| SCHEMBL3300908 | 0.81 | NPC1 (0.58) | MAPTNAMPTSLC18A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | MAPT 2115/4885NAMPT 165/4885ALDH1A1 314/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | MAPT 1986/4885NAMPT 161/4885ALDH1A1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.